Sign In
Buy NPCE
$12.95
+0.0100 (+0.0773%)
At Close: Nov 17, 2025
Y Intercept Hong Kong Ltd Takes Position in NeuroPace, Inc. $NPCE
03:40am, Thursday, 06'th Nov 2025
Y Intercept Hong Kong Ltd bought a new stake in shares of NeuroPace, Inc. (NASDAQ: NPCE) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript
11:06pm, Tuesday, 04'th Nov 2025
NeuroPace, Inc. ( NPCE ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Scott Scaper Joel Becker - CEO, President & Director Patrick Williams - Chief Financial Officer Confere
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
07:21pm, Tuesday, 04'th Nov 2025
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.19 per share a year ago.
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
04:05pm, Tuesday, 04'th Nov 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
08:00am, Wednesday, 22'nd Oct 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financ
NeuroPace to Participate in Upcoming Healthcare Conferences
08:00am, Thursday, 28'th Aug 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t
NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript
09:50pm, Tuesday, 12'th Aug 2025
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joel D. Becker - CEO, President & Director Patrick F.
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
06:26pm, Tuesday, 12'th Aug 2025
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago.
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
04:05pm, Tuesday, 12'th Aug 2025
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
07:30am, Friday, 01'st Aug 2025
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
10:00am, Wednesday, 02'nd Jul 2025
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to co
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
10:00am, Friday, 27'th Jun 2025
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to
NeuroPace Announces Strategic CFO Transition
04:05pm, Tuesday, 24'th Jun 2025
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
03:42am, Tuesday, 24'th Jun 2025
LOS ANGELES , June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ("N
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
12:49pm, Monday, 23'rd Jun 2025
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors a
